Physician profile
John M Ryden
NPI 1578589255
$551.86
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.20 · 2020: $16.07 · 2021: $131 · 2022: $120 · 2023: $110 · 2024: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $80.52 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.44 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.63 | 2023-2024 | Eliquis, Camzyos |
| Travere Therapeutics, INC. | $50.68 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $45.86 | 2022-2024 | Airsupra |
| Exact Sciences Corporation | $41.76 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $33.26 | 2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $29.30 | 2019-2024 | |
| Novo Nordisk INC | $26.32 | 2021 | |
| Astellas Pharma US INC | $23.43 | 2023 | Veozah |
| Neurocrine Biosciences, INC. | $17.26 | 2024 | Ingrezza |
| Amarin Pharma, INC. | $16.07 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.86 | 2019 | |
| Mylan Specialty L.P. | $15.36 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.45 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $13.06 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ryden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.